248 Early detection of chemotherapeutic skin toxicities in social health networks using deep learning

Cutaneous adverse drug reactions (ADRs) occur in nearly all patients undergoing anti-cancer therapy, contributing to morbidity, therapy disruptions, and rising health care costs. ADR characterization is hampered by clinical trials underpowered to detect rare events, division of patients across institutions, patient exclusion from trials, publication editorial delays, and infrequent dermatologist participation in oncologic care. Early ADR recognition could substantially improve health outcomes and decrease societal costs.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research